As coronárias derivam do proepicárdio, uma estrutura formada por precursores dos constituintes de vasos coronários, células endoteliais e musculares lisas (CoSMC). In vivo observa-se um marcante atraso entre a diferenciação endotelial e a integração de CoSMC à parede do vaso. O objetivo deste trabalho foi identificar os mecanismos que inibem a diferenciação a CoSMC in vivo. Baseados na perda progressiva da expressão de raldh2, a principal enzima de síntese de ácido retinóico (AR), nós exploramos a sinalização por AR como um possível inibidor da diferenciação a CoSMC. Através de um vetor adenoviral de expressão de raldh2 e da inibição in vivo da síntese de AR nós demonstramos que a sinalização por AR bloqueia a diferenciação a CoSMC dos precursores coronários. Nós também identificamos o VEGF como um fator chave no controle da diferenciação a CoSMC. Em conjunto, nossos dados suportam o modelo que a síntese de AR e VEGF durante o desenvolvimento cardíaco foi co-optada para o bloqueio da diferenciação a CoSMC até o estabelecimento de uma vasta malha vascular. / Coronary vessels derive from the proepicardium (PE), a structure formed by precursor of coronary vessels cells, endothelial and smooth muscle cells (CoSMC). In vivo there is a clear gap between the endothelial differentiation and the integration of CoSMC into the vascular tubes. The aim of this work was to understand the mechanisms controlling the delayed in vivo CoSMC differentiation. Based on the progressive loss of expression of raldh2, the main retinoic acid (RA) synthesizing enzyme, we explored the RA signaling as a possible candidate inhibitor of CoSMC differentiation. Using a adenoviral raldh2 expression system and in vivo inhibition of RA synthesis we showed that RA signaling act as a brake to slow CoSMC differentiation in PE-derived cells. We also identified VEGF as key factor acting on the control of CoSMC differentiation. Together our results support a model that AR and VEGF synthesis during cardiac development was co-opted to block the CoSMC differentiation of coronary precursors before an extensive endothelial network of tubes is established.

L’AMPc est un second messager exerçant un rôle vasculoprotecteur majeur, par ses effets relaxants et inhibiteurs de la prolifération et de la migration cellulaires. Les concentrations intracellulaires d’AMPc sont finement régulées par leur synthèse via les adénylates cyclases et leur dégradation par les phosphodiestérases (PDEs). Nous avons évalué l’impact de l’environnement cellulaire sur la voie de signalisation couplée au récepteur β-adrénergique (β-AR/AMPc/PDE) dans les cellules musculaires lisses vasculaires (CMLVs), ainsi que les altérations potentielles de celle-ci en situation pathologique d’insuffisance cardiaque (IC).Notre première étude montre que dans les CMLs d’aorte de rat en culture, adoptant un phénotype synthétique, la voie de signalisation β-AR/AMPc/PDE est hautement modulée par la densité cellulaire Ainsi, une faible densité cellulaire est associée à une régulation négative de l’expression fonctionnelle du récepteur β1-AR, à une activité hydrolytique des PDEs-AMPc plus faible et à des concentrations d’AMPc intracellulaire plus élevées que celles observées dans des cellules confluentes.Notre deuxième étude montre que dans l’aorte de rat, l’IC est associée à une dysfonction endothéliale (DE), une hyperréactivité aux agents contractants et une altération de la fonction et de l’expression des PDEs-AMPc. Nos résultats suggèrent que l’altération de la voie du NO/GMPc suite à la DE conduit à une hyper-activation de la PDE3, qui masque la fonction de la PDE4 et altère la relaxation β-AR.L’ensemble de ce travail met en évidence le rôle critique de l'environnement cellulaire dans le contrôle de la voie β-AR/AMPc/PDE des CMLVsMots clés : Muscle lisse vasculaire, récepteur β-adrénergique, AMPc, phosphodiestérases, densité cellulaire, insuffisance cardiaque / CAMP is second messenger which plays a prominent vasculoprotective role by its relaxing effects and inhibition of cell proliferation and migration. Intracellular cAMP level is regulated by its synthesis by adenylate cyclase and its degradation by phosphodiesterases (PDEs). We evaluated the influence of cellular environment on signaling pathway coupled to β-adrenoceptors (β-AR/cAMP/PDE) on vascular smooth muscle cells (VSMCs), as well as potential alterations in heart failure (HF).The first study showed that in cultured rat aortic SMCs exhibiting synthetic phenotype, the β-AR/cAMP/PDE signaling pathway is highly modulated by the cellular density.Thus, the low density state being associated to a downregulation of the β1-AR, a lower cAMP-PDE activity and a higher basal [cAMP]i compared to confluent cells.Our second study showed that in rat aorta, HF is associated with endothelial dysfunction, hyper-reactivity to contractile agents and an alteration of function and expression of cAMP-PDEs. Our results suggest that NO/cGMP pathway alteration following the ED in HF leads to hyper-activation of PDE3 which masks PDE4 function and alters β-adrenoceptor relaxationThus, our works highlights the critical role of the cellular environment in controlling the vascular β-AR signaling.Keywords: Vascular smooth muscle, β-adrenoceptor, cAMP, phosphodiesterases, cellular density, heart failure.

Une augmentation de la concentration de l’angiotensine II (Ang II) contribue à la prolifération, la migration et l’hypertrophie des cellules musculaires lisses vasculaires (CMLVs) par l’activation des voies des mitogen-activated protein kinases (MAPK) et de la phosphoinositide 3-kinase (PI3K)/protéine kinase B (PKB/Akt). L’Ang II induit l’activation du facteur de transcription early growth response protein-1 (Egr-1) et sa suractivation est remarquée dans les lésions athérosclérotiques et les modèles animaux de lésions vasculaires. La régulation des facteurs de transcription est effectuée par des histones désacétylases (HDACs) qui désacétylent les lysines des histones et protéines non-histones. L’Ang II induit la phosphorylation et l’export nucléaire de la classe IIa des HDACs, particulièrement les HDAC5, et une augmentation de celles-ci est observée dans les maladies vasculaires. L’Ang II est un puissant activateur des voies des MAPK et de la PI3K/Akt, toutefois l’implication de ces voies dans la phosphorylation des HDAC5 et l’expression de l’Egr-1 dans les CMLVs reste inexplorée. Dans cette étude, l’Ang II a induit la phosphorylation des HDAC5 sur la sérine 498 dans les A10 CMLVs. Un blocage pharmacologique de l’extracellular signal-regulated kinase 1/2 (ERK1/2) par U0126 n’a montré aucun effet significatif sur la phosphorylation et l’exclusion nucléaire des HDAC5 induite par l’Ang II. Par contre, l’inhibition de la voie PI3K par wortmannin, de l’Akt par SC66 ou le knockdown de l’Akt par des petits ARN interférents (siRNA) a atténué la phosphorylation et l’export nucléaire des HDAC5 induits par l’Ang II. Par ailleurs, l’inhibition de l’Akt ou le knockdown de cette kinase a diminué l’expression de l’Egr-1 induite dans les CMLVs stimulées par l’Ang II. L’inhibition des HDACs de la classe IIa par MC1568 ou TMP-195 ou bien le knockdown des HDAC5 a diminué l’expression de l’Egr-1 induite par l’Ang II. De plus, le blocage de l’export nucléaire des HDAC5 par la leptomycine B ou la KPT-330 a empêché la localisation cytoplasmique des HDAC5 et a atténué l’expression de l’Egr-1 en réponse à une stimulation de l’Ang II. L’hypertrophie vasculaire induite par l’Ang II a pu être inhibée par la suppression de l’HDAC5 et l’Egr-1. En conclusion, l’Ang II induit la phosphorylation et l’exclusion nucléaire des HDAC5 par la voie PI3K/Akt et non celle de ERK1/2; de plus, l’Ang II induit l’expression de l’Egr-1 à l’aide des HDAC5 via la voie Akt contribuant ainsi à l’hypertrophie des CMLVs. / Elevated concentration of angiotensin II (Ang II) contributes to vascular smooth muscle cells (VSMCs) proliferation, migration and hypertrophy by the activation of the mitogen-activated protein kinases (MAPK) and phosphoinositide 3-kinase (PI3K)/protein kinase B (PKB/Akt) pathways. Ang II induced the expression of early growth response protein-1 (Egr-1), which is a transcription factor that is upregulated in atherosclerosis lesions and in animal models of vascular injuries. The activation or derepression of gene transcription is mediated by histone deacetylases (HDACs), which deacetylate lysine residues from histone and non-histones proteins. Ang II-induced the phosphorylation and nuclear export of class IIa HDACs, notably HDAC5, and its elevated activation is observed in vascular pathologies. Ang II is a potent activator of the MAPK and PI3K/Akt pathways, however their implication in the phosphorylation of HDAC5 and Egr-1 expression in VSMCs remain unexplored. In this study, Ang II-induced HDAC5 phosphorylation at serine 498 in A10 VSMCs and pharmacological blockade of the extracellular signal-regulated kinase 1/2 (ERK1/2) by U0126 did not affect the phosphorylation and nuclear exclusion of HDAC5 in response to Ang II. Whereas, pharmacological inhibition of the PI3K by wortmannin, Akt by SC66 or small interfering RNA (siRNA)-induced silencing of Akt attenuated Ang II-induced HDAC5 phosphorylation and its nuclear export. Furthermore, inhibition or knockdown of Akt suppressed Ang II-induced Egr-1 expression. In addition, the inhibition of class IIa HDAC5 by MC1568, TMP-195 or HDAC5 knockdown by siRNA reduced Ang II-induced Egr-1 expression. The blockade of the nuclear export of HDAC5 by leptomycin B or KPT-330 prevented the cytoplasmic localization of HDAC5 and attenuated the expression of Egr-1 by Ang II in VSMCs. Moreover, HDAC5 or Egr-1 depletion prevented Ang II-induced cell hypertrophy. In summary, Ang II-induced HDAC5 phosphorylation and its nuclear export is mediated by the PI3K/Akt and not the ERK1/2 pathway, in addition, Ang II-induced Egr-1 expression involves the implication of HDAC5 via the Akt pathway which subsequently leads to VSMC hypertrophy.

Les antagonistes des récepteurs aux minéralocorticoïdes (MR) appartiennent à l'arsenal thérapeutique pour le traitement de diverses maladies cardiovasculaires, mais les mécanismes conférant leurs effets bénéfiques sont encore mal compris. Une partie de ces effets peuvent être liée à la régulation de l'expression du canal Ca2+ de type L Cav1.2, largement impliqué dans l'insuffisance cardiaque et l'hypertension. Nous montrons que MR fonctionne comme un facteur de transcription transformant le signal de l'aldostérone dans l'utilisation du 'cardiaque' promoteur alternatif P1, dirigeant l'expression du long N-terminal transcrit (Cav1.2-LNT. L'aldostérone augmente de façon concentration- et de temps dépendente l'expression de Cav1.2-LNT dans les cardiomyocytes en raison de l'activation du promoteur P1, par interactions des MR avec des séquences spécifiques de l'ADN sur le promoter P1. Ce mécanisme de cis-régulation induit l'activation de promoteur P1 dans les cellules vasculaires conduisant à une nouvelle signature moléculaire de Cav1.2-LNT associé à une sensibilité réduite aux bloqueurs des canaux Ca2+. Ces résultats révèlent Cav1.2-LNT comme une cible minéralocorticoïde spécifique qui pourrait influencer sur l'éfficacité thérapeutique dans les maladies cardiovasculaires. / The mineralocorticoid receptor (MR) antagonists belong to the current therapeutic armamentarium for the management of cardiovascular diseases, but the mechanisms conferring their beneficial effects are still poorly understood. Part of these MR effects might be related to the L-type Cav1.2 Ca2+ channel expression regulation, critically involved in heart failure and hypertension. Here, we show that MR acts as a transcription factor triggering aldosterone signal into specific alternative 'cardiac' P1-promoter usage, given rise to long (Cav1.2-LNT) N-terminal transcripts. Aldosterone increases Cav1.2-LNT expression in cardiomyocytes in a time- and dose-dependent manner due to MR-dependent P1-promoter activity, through specific DNA sequence-MR interactions. This cis-regulatory mechanism induced a MR-dependent P1-promoter switch in vascular cells leading to a new Cav1.2-LNT molecular signature with reduced Ca2+ channel blocker sensitivity. These findings uncover Cav1.2-LNT as a specific mineralocorticoid target that might influence the therapeutic outcome of cardiovascular diseases.

Indiana University-Purdue University Indianapolis (IUPUI) / Factors released from coronary perivascular adipose tissue (PVAT), which surrounds large coronary arteries, have been implicated in the development of coronary disease. However, the precise contribution of coronary PVAT-derived factors to the initiation and progression of coronary vascular dysfunction remains ill defined. Accordingly, this investigation was designed to delineate the mechanisms by which PVAT-derived factors influence obesity-induced coronary smooth muscle dysfunction. Isometric tension studies of coronary arteries from lean and obese swine demonstrated that both lean and obese coronary PVAT attenuate vasodilation via inhibitory effects on smooth muscle K+ channels. Specifically, lean coronary PVAT attenuated KCa and KV7 channel-mediated dilation, whereas obese coronary PVAT impaired KATP channel-mediated dilation. Importantly, these effects were independent of alterations in underlying smooth muscle function in obese arteries. The PVAT-derived factor calpastatin impaired adenosine dilation in lean but not obese arteries, suggesting that alterations in specific factors may contribute to the development of smooth muscle dysfunction. Further studies tested the hypothesis that leptin, which is expressed in coronary PVAT and is upregulated in obesity, acts as an upstream mediator of coronary smooth muscle dysfunction. Long-term administration (3 day culture) of obese concentrations of leptin markedly altered the coronary artery proteome, favoring pathways associated with calcium signaling and cellular proliferation. Isometric tension studies demonstrated that short-term (30 min) exposure to leptin potentiated depolarization-induced contraction of coronary arteries and that this effect was augmented following longer-term leptin administration (3 days). Inhibition of Rho kinase reduced leptin-mediated increases in coronary artery contractions. Acute treatment was associated with increased Rho kinase activity, whereas longer-term exposure was associated with increases in Rho kinase protein abundance. Alterations in Rho kinase signaling were also associated with leptin-mediated increases in coronary vascular smooth muscle proliferation. These findings provide novel mechanistic evidence linking coronary PVAT with vascular dysfunction and further support a role for coronary PVAT in the pathogenesis of coronary disease.

No description available.

Spiral-artery (SA) remodeling is a fundamental process during pregnancy that involves the action of cells of the initial vessel, such as vascular smooth-muscle cells (VSMCs) and endothelial cells, but also maternal immune cells and fetal extravillous trophoblast cells (EVTs). Mast cells (MCs), and specifically chymase-expressing cells, have been identified as key to a sufficient SA remodeling process in vivo. However, the mechanisms are still unclear. The purpose of this study is to evaluate the effects of the MC line HMC-1 and recombinant human chymase (rhuCMA1) on human primary uterine vascular smooth-muscle cells (HUtSMCs), a human trophoblast cell line (HTR8/SV-neo), and human umbilical-vein endothelial cells (HUVEC) in vitro. Both HMC-1 and rhuCMA1 stimulated migration, proliferation, and changed protein expression in HUtSMCs. HMC-1 increased proliferation, migration, and changed gene expression of HTR8/SVneo cells, while rhuCMA treatment led to increased migration and decreased expression of tissue inhibitors of matrix metalloproteinases. Additionally, rhuCMA1 enhanced endothelial-cell-tube formation. Collectively, we identified possible mechanisms by which MCs/rhuCMA1 promote SA remodeling. Our findings are relevant to the understanding of this crucial step in pregnancy and thus of the dysregulated pathways that can lead to pregnancy complications such as fetal growth restriction and preeclampsia.

Peripheral Artery Disease is a very serious disease characterized by an arterial occlusion due to atherosclerotic plaques. In response to an arterial occlusion, arteriogenesis occurs, causing smooth muscle cells to transition from a contractile to synthetic state. Also following an arterial occlusion, functional impairment was seen in the collateral circuit. An immunofluorescence protocol was developed in order to assess the impact of collateral enlargement (arteriogenesis) on smooth muscle phenotype at various time points. Smooth muscle α-actin was used to mark all smooth muscle cells, Ki-67 was used to label proliferating smooth muscle cells, and a fluorescent nuclear stain was used to quantify the number of cells present. Samples of the profunda femoris and gracilis were dissected from each mouse hind limb (one ligated, one sham) at three different time points: 3 days, 7 days, and 14 days after a femoral artery ligation surgery. Smooth muscle cell phenotype and luminal cross-sectional area were assessed in the profunda femoris and the midzone of the gracilis collaterals. Smooth muscle cells were proliferating at 3 and 7 days following the occlusion in the gracilis collaterals and significant collateral vessel growth was observed over the two week period. No proliferation was observed in the profunda femoris and although there was an increasing trend in vessel size over the two week period, the averages were not significantly different. The phenotypic transition of the smooth muscle cells was not the cause of vascular impairment in the collateral circuit. This shows that further research is needed to characterize impairment in the collateral circuit.

No description available.

No description available.